Skip to main content

Next Step For Pfizer After Nestle Sale: Get Drugs Approved, Sell Them

Pfizer announced today that it is selling its nutritional business, a leading maker of infant formula in Asia, Europe, and Latin America, to Nestle for $11.85 billion or nearly 20 times the division’s EBITDA. That’s nearly $2 billion more than analysts were forecasting the business might get last year, when I first reported on the idea that the drug giant might be spinning off non-core divisions. The Pfizer baby formula unit is expected to generate $2.4 billion in sales this year.


That Pfizer got such a good price is obviously a win for investors. The company will be using the money to buy back shares, according to a statement by chief executive Ian Read – unless, he says, he can find a better way to put it to use. But shares edged down sixteen cents to $22.40 this morning, so, obviously, this victory was already baked in.
What’s next? For one thing, investors are likely to turn their eyes to another sale. Pfizer has already said it will also explore options for its animal health business, which sells veterinary drugs. Last year, I pegged the value of this $3.9 billion (sales) division at $16 billion. There could be more upside there.
A more important question – really, the big, meta-argument around both asset divestitures – is whether the world’s largest drug company will be able to go even further in taking itself apart. The big bull argument is that Pfizer will eventually get rid of its consumer health division too, and then build up its established products business into a generics business that can also be sold or spun off. That would leave a smaller, faster-growing pharmaceutical company. Some Wall Street analysts, including Jami Rubin at Goldman Sachs, have been fans of this idea for years.
Richard Evans, of research firm Sovereign & Sector, has made the counter-argument that even if you spin off all the really old, nearly generic drugs, most of Pfizer’s products are still pretty old, and that the company’s research and development spending won’t produce enough hits to make that new, smaller company, nearly so compelling.
Lest we forget, the key to running a successful drug company is not spinning off existing divisions but inventing new drugs, bringing them to market, and then selling them. Key events by which Pfizer’s research efforts will be judged are approaching.
On May 9, the company’s key rheumatoid arthritis pill, tofacitinib, will go before a panel of experts chosen by the Food and Drug Administration. The potential for this drug is very big, but the big question is whether it will be able to compete directly with Abbott Laboratories’ injectible Humira – expected to soon be the best-selling drug in the world – or whether it will be relegated to use afterward, at least at first.
Also this summer, Eliquis, a new blood thinner for patients at high risk of stroke Pfizer has developed with Bristol-Myers Squibb, could be approved; the FDA is due to make a decision on June 28. Also worth watching: a study, due to complete in August 2013 with results due in December 2014, of whether the company’s Prevnar 13 vaccine prevents pneumonia in adults. Sales of other new products, like cancer drug Xalkori, will also be key.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...
4 comments
Read more